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ABSTRACT
VITAMIN D LEVELS AND RISK OF DYSLIPIDEMIA AMONG US CHILDREN
WITH DIABETES AND OBESITY.
MAY 2011
ELSINA E. HAGAN, B.SC. (HONS), UNIVERSITY OF GHANA, LEGON
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Lisa Chasan-Taber (ScD)
Dyslipidemia is increasing among U.S. children, and the prevalence is highest
among children with diabetes and obesity. Recently, vitamin D deficiency has been
suggested as a possible dietary risk factor for dyslipidemia. Despite the high prevalence
of vitamin D deficiency amongst children, virtually no studies have evaluated the
association between vitamin D and dyslipidemia among children. We evaluated the
vitamin D and dyslipidemia relationship among 240 children and adolescents aged 2
through 21 years who were outpatients of a pediatric endocrinology unit at a large tertiary
care facility in Western Massachusetts from April 2008 to April 2010. Eligible children
were those with either obesity and/or type 1 or 2 diabetes mellitus. A total of 17.4% of
children had severe (<15.0 ng/ml) vitamin D deficiency, 19.2% had moderate (15.0-19.9
ng/ml) deficiency, 36.3% were insufficient (20.0-29.9 ng/ml), and 27.1% had normal
(≥30.0 ng/ml) levels. A total of 28.8% of children had high total cholesterol (TC ≥180
mg/dL), 19.6% had high triglycerides (TG; <10years: ≥110 mg/dL, ≥10years: ≥130
mg/dL), 21.3% had low high density lipoprotein (HDL <40 mg/dL), and 6.7% had high
low density lipoprotein (LDL ≥130 mg/dL). Moderate vitamin D deficiency was
associated with increased risk of high TC (adjusted odds ratio [OR
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adj]

= 2.9, 95%

confidence interval (CI): 1.0, 8.8) compared to children with normal vitamin D levels.
Severe vitamin D deficiency was associated with an increased risk of low HDL (OR adj =
3.5, 95% CI: 1.0-12.3) and high TG (OR

adj

= 11.7, 95% CI: 1.9, 70.3) compared to

children with normal vitamin D levels. Children with moderate vitamin D deficiency had
approximately 3-fold increased risk of high TC compared to children with normal
vitamin D levels. In comparison to children with normal vitamin D levels, severe vitamin
D deficiency was associated with a strong and significant increased risk of low HDL and
high TG; with a significant dose-response relationship. Additionally, in linear regression
analyses, we found that an increase in vitamin D deficiency was associated with a
significant mean increase in all four measures of dyslipidemia. Vitamin D adequacy may
reduce the risk of dyslipidemia in children.
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CHAPTER I

INTRODUCTION

Dyslipidemia is a metabolic disorder of lipoprotein metabolism which results in
abnormal excesses of: total cholesterol (TC), low-density lipoprotein cholesterol (LDLC), or triglycerides, or a deficiency in high-density lipoprotein cholesterol (HDL-C) (1).
Approximately 10% of US children are affected by hyperlipidemia; a type of
dyslipidemia characterized by elevated levels of blood lipids (2, 3). Dyslipidemia is one
of the key factors considered by the National Cholesterol Education Program Adult
Treatment Panel (NCEP - ATP III) in defining metabolic syndrome. The US prevalence
of metabolic syndrome in adults ≥ 20 years is 20% (3). In US adolescents ≤ 20 years,
6.4% can be classified as having metabolic syndrome based on age modified NCEP ATP III criteria, out of which 50% are severely obese children and adolescents (3).
Childhood dyslipidemia is associated with the risk of developing CVD in
adulthood (4). Familial hypercholesterolemia (FH), familial combined hyperlipidemia
(FCHL), familial hyperglyceridemia and hyper-apoprotein – B, are some commonly
inherited lipoprotein disorders observed in children of parents with premature
cardiovascular disease (CVD) which makes these youth at high risk of developing CVD
in the future (1, 2, 5).
The primary known risk factors for dyslipidemia include genetic disorders of lipid
metabolism such as familial hypercholesterolemia. However secondary causes of
dyslipidemia in adolescents are diabetes, cigarette smoking and anorexia nervosa. In view
of the rising trends in dyslipidemia in children and adolescents, there is the need to
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continually identify new risk factors for dyslipidemia in this population. Vitamin D
deficiency is thought to be one of the newer risk factors for dyslipidemia in children and
adolescents, especially for those with other underlying metabolic syndromes.
Vitamin D deficiency, mainly in the form of rickets, became epidemic in the US
at the end of the 19th century. In children and adolescents, extreme cases of vitamin D
deficiency result in rickets and, in adults it leads to osteomalacia. However, in recent
years, there has been increasing interest in the association between vitamin D deficiency
and diseases, such as cardiovascular disease (CVD) (6). There is substantial evidence
suggesting that hypovitaminosis D (low levels of vitamin D) influences the development
of CVD after age 50 (6). In vitamin D deficient youths, successful repletion of vitamin D
has been shown to reduce the possibility of developing CVD in adulthood (6). Because
pathological evidence suggests that precursors of CVD start from childhood (6), these
findings support evaluating the association of vitamin D deficiency with CVD risk factors
(6).
However, to date no study has evaluated the relationship of vitamin D deficiency
with dyslipidemia, especially in children with obesity and / or diabetes. Therefore, we
evaluated the association between vitamin D deficiency and blood lipids among children
and adolescents, 2 through 21 years old, diagnosed with either diabetes and/or obesity.
Specifically our aims were to evaluate the association between vitamin D deficiency and
high density lipoprotein (HDL), low density lipoprotein (LDL), total cholesterol (TC) and
triglycerides (TG), among these high risk children. We used a cross-sectional study
design; data on serum 25(OH)Vitamin D levels as well as fasting (> 12 hours) blood lipid
levels were obtained via laboratory analysis and chart review of medical record from the
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Pediatric Endocrinology and Pediatric Weight Management Clinics, of the Baystate
Medical Center’s Children’s Hospital in Springfield, Massachusetts. The American
Academy of Pediatrics (AAP) and National Cholesterol Education Program (NCEP)
guidelines, were used in classifying blood lipid levels. This study base represented an
ethnically and socioeconomically diverse population of which majority were
predominantly non-Hispanic white and Asian.
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CHAPTER II

LITERATURE REVIEW

A.

Biological Evidence (Physiology) of the Association between Vitamin D

Levels and Dyslipidemia.
Dietary sources of vitamin D include oily fish, irradiated mushrooms, dairy foods
such as milk and eggs, whole grains and cereals as well as other fortified foods such as
juices (7). However, the bulk (90%) of vitamin D utilized by humans is obtained through
the synthesis of vitamin D in the skin through a sturdy photolytic procedure. This process
involves the action of sunlight (exposure to ultraviolet (UVB) radiation 290-315nm from
the sun) on a cholesterol derivative i.e. 7-dehydrocholesterol, present in the plasma
membrane of epidermal keratinocytes and dermal fibroblasts. Once the energy from the
sun has been absorbed by the double bonds in the “B ring” of the 7-dehydrocholesterol,
previtamin D is produced, which next gradually converted from one isomer to the other
(rearrangement of the double bonds and opening of the B rings) into vitamin D3 (7, 8).
The natural form of vitamin D produced from this photosynthesis in the skin is vitamin
D3, (this compound, 25-hydroxyvitamin D3 (25(OH)D3)), which in its present form is
metabolically inert or inactive, needs to be modified into its functional form in the body.
The form in which vitamin D is commonly monitored to assess vitamin D status of
patients is 25-hydroxyvitamin D3 (25 (OH) D3)) (8).
The exact mechanisms by which vitamin D deficiency influences dyslipidemia
have not been fully elucidated (9). However, three indirect mechanisms have being
suggested as possible ways in which vitamin D deficiency may influence blood lipid
4

metabolism or profiles. In terms of the first mechanism, Pittas et al. (2010), suggests a
possible direct mechanism in which vitamin D deficiency may influence the risk of
cardio-metabolic outcomes involving vitamin D receptor activation. This mechanism
though, poorly understood in relation to the influence of vitamin D on dyslipidemia, is
thought to be linked to how the vitamin D receptor influences other cardiometabolic
outcomes such as hypertension (10). In terms of this mechanism, cardiac myocytes,
endothelial, and smooth vascular muscle cells express both the vitamin D receptor and
the 1-α-hydroxylase enzyme which then activates the inactive circulating vitamin D
precursor (25(OH)D) into the active vitamin D metabolite and possibly increasing
lipoprotein lipase enzyme levels and subsequently decreasing TG levels (10).
A second possible mechanism suggests that vitamin D may decrease blood lipid
levels, specifically TG plasma levels, via regulation of vitamin D adipocytes (10). This
mechanism is as a result of the disruption of the mevalonate pathway (HMG-CoA
reductase pathway), by the effects of statin drug therapy, which function as inhibitors of
the 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase enzyme and
subsequently causes an increase in 7-dehydrocholesterol (10, 11). The excess 7dehydrocholesterol in the human body is then converted to 25-hydroxycholecalciferol by
the action of sunlight or the CYP11A1 enzyme (11). This action leads to an increase in
vitamin D levels in the body and a corresponding decrease in TG levels possibly due to
elevated levels of the lipoprotein lipase enzyme resulting from the disruption of the
mevalonate pathway (10, 11).

5

The third proposed mechanism linking vitamin D deficiency with dyslipidemia, is
via the elevation of peripheral insulin resistance in the body (11). This mechanism is also
poorly understood.
In summary three possible indirect mechanisms have been proposed linking
vitamin D to dyslipidemia: the first involves the activation of the vitamin D receptor, the
second is as a result of the disruption of the mevalonate pathway (HMG-CoA reductase
pathway) as a result of statin drug therapy, and the third mechanism is as a result of the
elevation of peripheral insulin resistance in the body.

B.

Epidemiology of Vitamin D Levels and Dyslipidemia (Abnormal Lipid

Levels)
To the best of our knowledge, over the past five years eleven epidemiological
studies have evaluated the association between vitamin D and cardiovascular risk factors
including dyslipidemia (6, 12-21), eight of which were US based (6, 12-15, 18, 19, 21)
and 3 international ones (16, 17, 20).
Out of the eight epidemiological studies conducted amongst older populations
mainly ≥ 20 years, six were conducted cross-sectionally (12, 13, 16, 17, 19, 21), while
only two (18, 20) prospectively evaluated the association between vitamin D deficiency
and dyslipidemia. Two out of these eight studies in adults, found a negative association,
(12, 21), another two found a positive association; (17, 18), while the remaining four;
(13, 16, 19, 20) found null associations between dyslipidemia and vitamin D deficiency.
Despite immense recent interest in vitamin D deficiency and dyslipidemia in
children and adolescents, only three out of the eleven epidemiologic studies investigated
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this association in children and adolescents ≤ 20 years old; Kumar et al (2009), Reis et al
(2009) and Ashraf et al (2009).
Due to the conflicting or inconsistent epidemiological evidence and the limited
number of epidemiological studies relevant to our population, we included findings from
studies in these eight older populations (12, 13, 16-21) that evaluated vitamin D
deficiency and dyslipidemia in our literature review. To the best of our knowledge, there
are no previous studies evaluating the relationship between vitamin D deficiency and
dyslipidemia, specifically looking at abnormal blood lipid (high density lipoproteins
(HDL), low density lipoproteins (LDL), total cholesterol (TC) and triglycerides (TG))
levels, in children with diabetes and obesity who are at high risk of developing
cardiovascular disease in the US. However a number of studies have focused on the
association between vitamin D deficiency and dyslipidemia in older populations (e.g.
people 20 years and older) (12, 13, 16-21).
The first notable epidemiologic study of this association in children was a crosssectional study designed and conducted by Kumar et al (2009), in a nationally
representative sample of 6275 US children aged 1 to 21 years, in the National Health and
Nutrition Examination Survey in 2001 to 2004. The Diasorin assay was used in assessing
the serum vitamin D levels. Study subjects were categorized into three groups based on
these vitamin D status: vitamin D deficient (< 15 ng/mL), and vitamin D insufficiency
(15-29 ng/mL), vitamin D sufficiency (>30 ng/mL) (15, 22). Vitamin D supplement use
was also accessed via self reported questionnaire and pill bottle review. Serum HDL and
TC were assessed using the Beckman Synchron LX20 assay. Children with diabetes were
eligible for the study if they met all other requirements.
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In a multivariable-adjusted analysis children and adolescents, with vitamin D
insufficiency or deficiency were more likely to have lower levels of high-density
lipoprotein cholesterol (HDL-C) lipid levels in comparison to children with sufficient or
normal vitamin D levels (difference: -2.29 mg/dL (95% CI -3.57 to -1.01) , p = 0.001)
and (difference: -3.03 mg/dL (95% CI -5.02 to -1.04) , p = 0.004) respectively (15).
Similarly total cholesterol was higher among vitamin D sufficient children compared to
vitamin D insufficient; (difference: -3.66 mg/dL (95% CI -7.09 to -0.23) , p = 0.04) in a
multivariable adjusted analysis (15). Hence this implied that vitamin D insufficiency and
deficiency, was statistically significantly associated with lower levels of high density
lipoprotein, additionally vitamin D insufficiency was also significantly associated with
lower levels of total cholesterol in children and adolescents. After excluding all obese
children from their analysis, as a means of controlling for residual confounding, the
observed relationships between vitamin D insufficiency and deficiency with both TC and
HDL levels were similar to that described previously for the entire study sample. This
implied that irrespective of a child or adolescent’s adiposity (being obese or non obese),
vitamin D insufficiency and deficiency were significantly associated with low levels of
HDL, whiles vitamin D insufficiency was also significantly associated with low levels of
TC.
This study was limited by the lack of information on the seasons in which the
vitamin D measures were taken. This is relevant because vitamin D levels vary greatly
with sunlight exposure. In addition the measures obtained for 25(OH)D levels, may have
been higher than the average 25(OH)D levels in the population, because screening and
enrollment of participants from the northern states in the NHANES study occurred during
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the summer. Finally, this study did not assess TG and LDL but only focused on HDL and
TC which may limit its generalizability to adolescents whose dyslipidemia is as a result
of an abnormality in the levels of LDL and TG.
In the second of the three studies conducted among children and adolescent
populations to evaluate the association between vitamin D deficiency and blood lipid
levels, Reis et al. (2009), conducted a cross-sectional study amongst 3,528 adolescents
without a diagnosis of diabetes aged 12 through 19 years, who were participants in
NHANES (6). This study differed from the prior study in that it focused primarily on
adolescents but it was also based on the NHANES data and was conducted from 2001 to
2004. Serum vitamin D levels were assessed using radioimmunoassay techniques.
Abnormal blood lipid levels for HDL-C and TG were ascertained using the National
Cholesterol Education Program Adult Treatment Panel III definition modified for age:
HDL-C < 40 mg/dL and TG > 110 mg/dL (6). For analytical purposes the vitamin D
levels measured were classified into quartiles, with quartile I, II, III, and IV representing
a vitamin D level of < 15.00 ng/mL, 15 to 21 ng/mL, 21 to 26 ng/mL and >26.00 ng/mL
respectively. In comparison to adolescents in the highest quartile, those in the lowest
quartile of vitamin D had a 50% non statistically significant increased risk for low highdensity lipoprotein cholesterol levels (adjusted OR; 1.54, 95% CI: 0.99 to 2.39). Those in
the highest quartile of vitamin D level classification did not have a statistically significant
decreased risk of hypertriglyceridemia, when compared with those in the lowest quartile
(adjusted OR: 1.00 (CI: 0.49 to 2.04)) (6), adjusting for age, gender, race or ethnicity,
poverty-to-income ratio, and physical activity.
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Overall this study failed to find any statistically significant association between
low vitamin D levels or vitamin D deficiency and dyslipidemia as measured by variations
in TG levels, but did observe the suggestion of an association with low HDL-C levels.
This study also lacked information on season of vitamin D draw, therefore the observed
vitamin D levels may not be representative of the average values for the study population.
Finally, the study did not assess TC and LDL but only focused on HDL and TG which
may limit its generalizability to adolescents whose dyslipidemia is as a result of an
abnormality in the levels of LDL and TC.
The third study by Ashraf et al. (2009), conducted amongst 51 African American
obese female adolescents, was the only study that specifically evaluated the association
between vitamin D deficiency and cardiovascular risk factors, including the full blood
lipid profile; (TC, TG, HDL and LDL) in adolescent obese females (14). Participants had
a mean age of 14 + 2 years and mean body mass index (BMI) of 43.3 + 9.9 kg/m2. This
study utilized a cross-sectional study design, and collected two baseline serum samples of
both the blood lipid levels and vitamin D levels. Total serum 25-(OH)D was measured
using liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology (14).
A binary classification, with (25(OH)D < 15ng/mL) and (25(OH)D > 15ng/mL) as
cutoffs, was used in grouping study participants into deficient or sufficient vitamin D
levels respectively (14). This study failed to show an association between vitamin D
deficiency and blood lipid levels. The vitamin D deficient groups (n= 31) had a mean
value of 158.57+ 26.00 and 83.63+41.49 mg/dl for TC and TG respectively, 159.55 +
18.85 and 88.80 + 50.10mg/dl for TC and TG for those in the vitamin D sufficient group
(n= 20) (p=0.885 and p=0.693 respectively) (14). The vitamin D deficient groups (n= 31)
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had a mean HDL and LDL of; 44.34 + 8.56 and 95.69 + 26.17 mg/dl, respectively, as
compared to 43.35+9.31 and 98.50 + 21.02 mg/dl respectively for the subjects with
sufficient vitamin D (n=20), (p=0.701 and p=0.692 respectively) (14). After adjusting for
BMI, a non significant inverse correlation was noted for TC and vitamin D deficiency
(n= 50, r = -0.011 p=0.94), whereas a positive but non significant correlation was noted
for HDL (n = 49, r = 0.012 and p=0.94) and LDL (n= 49, r = 0.037 and p=0.80) as well
as TG (n = 50, r= 0.067 and p=0.64) respectively (14). These findings imply that Ashraf
et al (2009), found no significant association between serum 25 (OH) vitamin D and
either; TC, HDL, LDL or TG.
The restriction of the study population to African Americans, limited its
generalizability, to a racially diverse population of children with similar characteristics.
In summary, Kumar et al (2009), observed a significant difference in the decline
in high density lipoprotein (HDL) and total cholesterol levels amongst vitamin D
insufficient participants in comparison to vitamin D sufficient participants, additionally
vitamin D deficiency was observed to be associated with low levels of HDL cholesterol
irrespective of adiposity or obesity. Reis et al (2009), however, found no significant
associations between levels (quartiles) of vitamin D with either low high density
lipoprotein or high triglycerides levels. Similarly Ashraf et al (2009), found no significant
association between serum 25 (OH) vitamin D and either; total cholesterol, HDL, low
density lipoprotein or triglycerides. No previous studies have evaluated the association
between vitamin D deficiency and abnormal blood lipids levels among multiracial
children and adolescents with diabetes and or obesity, who are at high risk for
cardiovascular disease (CVD). The studies which have been conducted primarily
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assessed the association between vitamin D deficiency and blood lipid levels in mainly
adult populations. To the best of our knowledge two out of the three studies conducted in
children have failed to show any association between vitamin D and abnormal blood lipid
levels. These studies are however limited by inadequate assessment of vitamin D
deficiency because seasonal variations were not accounted for, and in some cases, had a
small sample size (6, 14, 15).

C.

Summary
The prevalence of dyslipidemia amongst children and adolescents, particularly

those with prevailing metabolic syndrome such as obesity and diabetes, is steadily
increasing in the US population. It is thought that there may be an association between
childhood dyslipidemia and the risk of developing CVD in adulthood. For this reason
studies have evaluated the possible role of vitamin D deficiency in the development of
CVD in children. Mechanisms include the role of cardiac myocytes, endothelial, and
smooth vascular muscle cells in the activation of both the vitamin D receptor and the 1-αhydroxylase enzyme which then activates inactive circulating vitamin D precursor
(25(OH)D) into active vitamin D metabolite and possibly increasing lipoprotein lipase
enzyme levels and subsequently decreasing TG levels (10). Another possible mechanism
is as a result of the disruption of the mevalonate pathway (HMG-CoA reductase pathway)
by the effects of statin drug therapy, which function as inhibitors of the 3-hydroxy3methylglutaryl coenzyme A (HMG-CoA) reductase enzyme and subsequently causes an
increase in 7-dehydrocholesterol (10, 11). The excess 7-dehydrocholesterol in the human
body is then converted to 25-hydroxycholecalciferol by the action of sunlight or the

12

CYP11A1 enzyme (11). This action leads to an increase in vitamin D levels in the body
and a corresponding decrease in TG levels possibly due to elevated levels of the
lipoprotein lipase enzyme resulting from the disruption of the mevalonate pathway (10,
11).
There is sparse epidemiologic data on the relationship between vitamin D
deficiency and dyslipidemia, and majority of prior studies have examined this association
among adults. Therefore we evaluated the association between vitamin D deficiency and
blood lipids among children and adolescents, aged between 2 through 21 years,
diagnosed with either diabetes and/or obesity, and at high risk for cardiovascular disease
(CVD).
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CHAPTER III

SPECIFIC AIM AND HYPOTHESES

The specific aim of our study was to evaluate the relationship between vitamin D
deficiency and dyslipidemia among US children and adolescents at high risk for
cardiovascular disease (CVD).
The specific hypotheses we addressed in the study were:
1) We hypothesized that vitamin D deficiency will be inversely related to high serum
high density lipoprotein (HDL) levels among children and adolescents at high risk
for CVD.
2) We also hypothesized that vitamin D deficiency will be positively related to high
serum low density lipoprotein (LDL), total cholesterol (TC) and triglycerides
(TG) levels among children and adolescents at high risk for CVD.
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CHAPTER IV

METHODS

A.

Cross-sectional Study Design, Setting and Population
We evaluated the relationship between vitamin D levels and blood lipid levels in

children and adolescents with diabetes and/or obesity, in a cross-sectional study design.
Two years (April 2008 through April 2010) of patient data were obtained from the
Pediatric Endocrinology and Pediatric Weight Management Clinics, of the Baystate
Medical Center. The data for this cross-sectional analysis were abstracted using a
retrospective chart review of medical records. The data used for this study consisted of all
data abstracted through January 24th, 2011.

B.

Patient Ascertainment
Patients eligible for the study were identified from the medical charts and records

using the International Classification of Diseases, 9th Revision (ICD-9) codes: ICD-9:
278.0 (obesity), 783.1 (abnormal weight gain), 250.02 (type 2 diabetes), 250.03 (IDDM
Type 1 without complications uncontrolled), 250.00 (type 2 diabetes, controlled),
251.1(hyperinsulinism), 250.01 (juvenile diabetes uncomplicated), 253.5 (diabetes
insipidus). This study was part of a larger study to evaluate the cardiovascular disease
risk factors in children and adolescents with diabetes and/or obesity. The parent study
also sought to investigate the effect of low vitamin D levels on levels of the parathyroid
hormone. Children were referred to this clinic if they had a diagnosis of either obesity or
diabetes that required medical intervention. Once referred to this specialized clinic,
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children began a weight and/or diabetes management regime as part of their treatment.
Data on exposure, outcome and covariates were collected from a routine screening
procedure for each child during the initial physician visits. Data on both the exposure
(vitamin D levels) and outcome (blood lipid profiles) as well as covariates such as
parathyroid levels and serum calcium for each patient was obtained via laboratory testing,
while data on some covariates such as age (verified from date of birth) gender, ethnicity
and vitamin D supplementation were self reported by patients. Other covariates such as
anthropometric measures (e.g. weight and height) were assessed by a trained nurse at the
time of physician visit and documented in the medical records of each patient.
Additionally, other covariates such as; body mass index (BMI), BMI- Z-score, glycated
or glycosylated hemoglobin (HbA1C), and season were calculated from the relevant
documented medical record data on patients. Physicians generally ordered a laboratory
profile test for each patient at the initial visit and, when necessary, these tests may be
repeated again during follow up visits at the physician’s discretion for therapy and
monitoring purposes. For each patient data for the first 25 (OH) D laboratory draw with
accompanying lipid blood profile levels were utilized in this study.
The study is restricted to out-patients of the clinic, aged 2 through 21 years,
diagnosed of obesity as defined by a BMI > 95th percentile, and/or type 1 diabetes
mellitus, or type 2 diabetes mellitus (based on these ICD-9 codes:278.0 (obesity), 783.1
(abnormal weight gain), 250.02 (type 2 diabetes), 250.03 (IDDM Type 1 without
complications

uncontrolled),

250.00

(type

2

diabetes,

controlled),

251.1(hyperinsulinism), 250.01 (juvenile diabetes uncomplicated), 253.5 (diabetes
insipidus), who in addition also had a documented laboratory measurement of 25-
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hydroxy vitamin D level (25(OH)D) during the study period. Exclusion criteria were
known gastrointestinal malabsorptive disorder (i.e. celiac disease, cystic fibrosis), known
parathyroid disease and pregnant adolescents. Also excluded were children and
adolescents, with a diagnosis of non-essential hypertension and those without a lipid
assessment within 1 month of the vitamin D assessment.
Data on exposure, outcome and covariates were obtained from three sources of
the Pediatric Endocrinology and Pediatric Weight Management Clinic’s patients
computer database; laboratory data was abstracted from the 1) Clinical Information
System (CIS) database and 2) Pediatric Endocrinology Dynamic Record Organizer
(PEDRO) database. Demographic information on patients, was drawn from both the
Baystate administrative computer database used by Baystate Medical Physician groups;
3) Centricity Business, and from CIS. The data obtained from these three sources; 1) CIS
database, 2) Pediatric Endocrinology Dynamic Record Organizer (PEDRO) database and
3) Centricity Business were merged to create one database for our analysis. These data
were entered into the database by trained nurses.

C.

Vitamin D Levels (Exposure) Assessment
Vitamin D levels were assessed as serum 25 hydroxyvitamin D (25(OH) D)

levels, collected from clinical data of laboratory results in CIS and PEDRO databases. All
the study exposure data consisted of only vitamin D 25(OH) D assays conducted at the
Baystate Hospital laboratory using the direct, competitive chemiluminescence
immunoassay (CLIA) technique with a reference range of 32 - 100 ng/mL. Laboratory
data was then entered into PEDRO, by a trained nurse and later abstracted for our data
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analysis by a trained investigator and verified by a trained physician. Serum vitamin D
levels was categorized into four groups, according to commonly utilized standard limits
as: 1) severe vitamin D deficiency; less than 25.00 nmol/liter (< 15.00 ng/ml), 2)
moderate vitamin D deficiency; 25.00–49.99 nmol/liter (15.00 –19.99 ng/ml), 3) vitamin
D insufficiency, 50.00 –74.99 nmol/liter (20.00 –29.99 ng/ml) and 4) vitamin D optimal
or normal range, at least 75.00 nmol/liter (≥30.00 ng/ml) similar to what has been done
by other authors (15). In a separate analysis from the above, vitamin D levels were
dichotomized as: (≥30.00ng/ml) representing normal vitamin D levels and <30.00ng/ml
representing vitamin D deficiency. Additionally further analyses were conducted
evaluating vitamin D levels as a continuous measure.

D.

Validity of Exposure Assessment
The Baystate reference laboratory utilizes an externally and internally validated

method; direct, competitive chemiluminescence assay (CLIA), for the 25(OH) vitamin D
(also known as calcidiol, or cholecalciferol) metabolites analysis. The reference range for
the CLIA analysis is 32-100 ng/mL.

E.

Dyslipidemia (Outcome) Assessment
Based on general recommendations for blood lipid analysis, all outcomes were

assessed using 12 hour fasting blood samples. All the lipid draws included in this study
were analyzed at the Baystate reference laboratory; triglyceride (TG) was assessed by
enzymatic colorimetric GPO/PAP technique. High and low density lipoprotein (HDL and
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LDL) was by spectrophotometric; diet homogenous; enzymatic colorimetric technique.
Total cholesterol (TC) was by enzymatic colorimetric techniques.
A binary classification of low (hypo) or high (hyper) was used in categorizing all
the four individual blood lipid levels of interest; low density lipoproteins (LDL), high
density lipoprotein - cholesterol (HDL-C), total cholesterol (TC) and triglycerides (TG).
High density lipoprotein - cholesterol (HDL-C) and triglycerides (TG) were
dichotomized using the National Cholesterol Education Program (NCEP), expert panel
on cholesterol levels in children and adolescents cutoff as; low HDL-C; < 40 mg/dL and
≥ 40 mg/dL as sufficient (4, 5). Two reference levels were used in determining
hypertriglyceridemia (high TG levels), based on age; the cutoff point in children aged 2
to < 10 years was ≥ 110 mg/dL and for children and adolescents aged 10 to 21 years the
cut point was defined as ≥ 130 mg/dL, which was equivalent to the NCEP definition for
high LDL (4, 5). Also based on the NCEP guidelines, high TC was defined as ≥ 180
mg/dL (4, 5). The NCEP cutoffs for high and low levels of the blood lipids represent
approximately the 95th and 5th percentiles, respectively of the general population.

F.

Validity of Outcome Assessment
The Baystate reference laboratory internally validates the manufacturer’s (Roche)

repeatability

(within

run

precision,

n=21)

and

intermediate

precision

(total

precision/between run precision/between day precision) coefficient of variation (CV)
periodically. The repeatability CV% for LDL, TC, TG and low HDL are approximately;
0.81, 0.8, 1.5 and 0.95, respectively whiles the intermediate precision CV% for LDL, TC,
TG and low HDL are approximately; 1.18, 1.7, 1.8 and 1.3 respectively. For the
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repeatability analysis, 21 human samples were run, whiles for each intermediate precision
run, triplicate aliquots were analyzed for 21 days at one run per day.

G.

Covariate Assessment
At the same time as the exposure and outcome assessments, data for covariates

were also abstracted from the Centricity Business, CIS and PEDRO medical records
database, for each eligible study participant (Table 1). The covariates of interests were
age, sex (gender), serum calcium levels, weight in kilograms, and height in centimeters,
body mass index (BMI), BMI Z-score, glycated or glycosylated hemoglobin (HbA1C),
parathyroid hormone (PTH) levels, vitamin D supplementation, seasons (the four
Northern American seasons; Winter, Spring, Summer and Fall) and ethnicity. Prior
studies have indicated that age, gender and ethnicity are strong predictors of dyslipidemia
in children and adolescents especially those with underlining chronic disease conditions
such as diabetes and obesity (14).

H.

Data Analysis Plan

Specific Aim: we evaluated the relationship between vitamin D levels and the risk
dyslipidemia (abnormal blood lipid levels) among US children and adolescents with
diabetes and obesity.

1.

Univariate Analysis

The number and percent of study participants according to inclusion and exclusion
criteria are presented in Table 2. The distribution (number and percent) of 25-OH vitamin
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D levels (Table 3), and the distribution of blood lipid levels (Table 4), in our study
population, are also presented. Both a Pearson’s and Spearman’s correlation analysis was
conducted to evaluate the correlation between continuous exposure and continuous
covariates (Table 8).

2.

Bivariate Analysis
We used the two sample t test for continuous covariates and the chi-square test to

assess categorical covariates as potential confounders by cross-tabulating them with
binary coded exposure variables (Table 5) and exposure variables categorized into four
sub-groups on the basis of the previously described standard cutoff values (Table 6), and
a two sample t test and Analysis of Variance (ANOVA), for continuous exposure and
categorical covariates (Table 7) to determine if the observed distribution within our 2X2
tables fits the expected distributions for large cell frequencies. A similar assessment was
also done for the outcome variables coded as binary outcome variables (Table 9). For
2X2 tables with small cell frequencies an appropriate test such as the Fisher’s exact test
was used for this analysis. The statistical significance of the differences in the
distributions for all categorical covariates are indicated by P-values. For continuous
covariates, we calculated two-group t test, to determine the statistical differences in
continuous outcome variables between levels of the covariates (Table 9). Pearson
correlation coefficients were used to assess the correlation between the continuous
exposure or covariate variables and blood lipid levels (Table 10).We also described the
distribution; number and percentage of the categorical and continuous exposure variable
within the outcome categories (Table 11).
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3.

Multivariable Analysis
We modeled the relationship between levels of vitamin D and all the four types of

blood lipids, independently by levels within the individual types. This analysis was done
separately for both categorical and continuous variables using unadjusted and adjusted
multiple logistic regression and only adjusted multiple linear regression analysis
respectively (Table 12 and 13). For the 25-OH vitamin D levels dichotomized based on
widely used cutoffs, the normal level served as the referent group which we compared to
the deficient group. Similarly the normal group within the second grouping of vitamin D
levels into four widely accepted categories also served as the referent group for
comparisons with the other three groups.
To evaluate confounders we used the backward elimination procedure; for both
the logistic and linear regression model building respectively, to evaluate the association
between vitamin D levels and the four blood lipid levels (TC, TG, HDL and LDL)
adjusting for relevant covariates in separate models. Vitamin D levels were modeled as a
dichotomous, a categorical and continuous variable respectively in separate models.
Appropriate dummy variables were created for categorical covariates. All the previously
mentioned variables (covariates) were evaluated for inclusion in the final multivariable
logistic regression model as potential confounders, using the backward elimination
selection method based on Likelihood ratio tests for logistic regression models and on
Partial Fisher’s (F) tests for the linear regression models. The assessment to determine if
each covariate should be included in the model was done by initially building univariate
logistic regression models for each covariate based on the assumption that all continuous
variables were linear in the logit. Covariates with p-value < 0.25 from the univariable
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logistic or linear regression model’s likelihood ratio tests or Partial Fisher’s (F) tests, as
well as other variables of known clinical significance or of relevance to the association
were included in the initial logistic and linear multivariable model respectively.
Next based on the Wald’s test p-values from the initial multivariable model, the
significance or relevance of each covariate in the model was tested, starting with the
covariate or set of dummy variables with the highest p-value. A Likelihood ratio test with
a p-value < 0.05 as the level of statistical significance was conducted to determine if the
covariate being tested should be included in the logistic regression model, changes in the
coefficients of the other covariates in the model was also considered in decision to retain
a covariate in the model. A covariate that caused >10% change in the coefficients of the
other covariates when exclude from the model was retained in the model to be evaluated
as a confounder. In a similar way as described above for the logistic regression models a
Partial Fisher’s (F) tests with a p-value < 0.05 was used as the level of statistical
significance in the linear regression model building procedure
This process was repeated until all the remaining covariates in the model were all
of statistical significance or of known clinical significance to the association. Other
covariates that were not included in the initial multivariable model due to lack of
statistical significance were then also tested using the backward elimination selection
process described above, any of these covariates that became statistically significant
based on the likelihood ratio test or the Partial Fisher’s (F) tests during these steps were
included in the model, despite their initial exclusion to obtain the preliminary main
effects model.
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To assess the assumption that continuous variables in the preliminary main effects
model, were linear in the logit scale, the design variable method was used, when this
yielded non linear graphs, next fractional polynomials were utilized to confirm the
linearity. In some instances in this analysis the assumption of continuous variables being
linear in the logit was met, but in instances where it was not met for some continuous
variables, these covariates were recoded using either quartiles or categorizations based on
cutoff points of inflections on the non linear graph. This recoding process yielded
multiple linear variables for the specific covariate that had been recorded which was now
included into the model as quartiles or categorical variables in the final main effects
multivariable model.
Possible effect modification by the interactions of pairs of covariates was also
tested. To evaluate the significance of hypothesized interactions in the logistic regression
models the Likelihood ratio tests was used and for the linear regression models the Partial
Fisher’s (F) tests was used, for comparison of the model including the interaction term to
the main effects model. An analysis that indicated that there were no plausible significant
effect modifiers of the association, hence no interaction terms were included in any of our
final multivariable models for the final analysis. Goodness of fit of the models were
assessed using the Hosmer-Lemeshow test. To assess model discrimination an Area
under ROC curve was generated. In addition the Hosmer-Lemeshow’s delta deviance test
was used to assess poorly fit points which were identified as those having significant
influence on the model deviance, in a similar way for the parameter estimates the
Pregibon’s delta beta test was used to detect influential points.
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To assess the effect of the previously identified influential observations on our
observed results a Sensitivity analysis was conducted to exclude these influential
observations from the model prior to refitting the model. However the identified
influential observations represented missing data hence the original final model was
maintained. Further sensitivity analysis was done to determine if the exclusion of
younger children (<10) or obese children and adolescents, from the final model changed
the estimated effects. This analysis also did not yield any different results, hence the
original final model was maintained.
Odds ratios and 95% confidence intervals were calculated for the logistic
regression analysis, whiles regression coefficients and 95% confidence intervals were
estimated for the linear regression analysis.
Stata version 11.0 was used for all analyses (Stata Corporation College Station,
TX). Two-sided p-values ≤ 0.05 were considered statistically significant, with no
adjustment for multiple comparisons.

I.

Significance
To the best of our knowledge, to date no study has evaluated the relationship

between vitamin D levels or deficiency, and abnormal blood lipid levels (dyslipidemia),
in children with metabolic syndromes such as obesity and diabetes. Given the growing
incidence of cardiovascular disease risk factors including dyslipidemia amongst children,
findings could inform more aggressive lifestyle and dietary interventions with vitamin D
supplementation to reduce the risk of dyslipidemia in high risk children. Other potential
benefits include the possibility to estimate the prevalence of vitamin D deficiency in this

25

unique population of children in relation to their risk of dyslipidemia. An added benefit
includes determination of whether the PEDRO database can be supported for future
clinical research purposes.

J.

Human Subjects Protection
This vitamin D study was approved by the Institutional Review Board (IRB) of

the Baystate Medical Center. A secondary analysis on the data collected was also
approved by the Institutional Review Board (IRB) of the School of Public health
Sciences, University of Massachusetts Amherst.
Strict measures were put in place to ensure confidentiality of patient data and
adherence to the IRB protocol. Patient data were coded and de-identified after abstracting
from the medical records into our database. The study database was securely stored on a
password protected Baystate Health Center computer, to which only approved study staff
had access to. Paper charts were immediately returned to the medical records office after
patient data was obtained in a Baystate office. All study personnel were trained in privacy
protocols.
With the exception of the unlikely occurrence of an accidental breach of
confidentiality or data sharing, there were no known potential risks to study participants
because there was no direct patient contact and no sensitive patient information was
accessed. Also the training of study personnel ensured the adherence to privacy protocols.
There also was minimal to no risks to the physical, psychological, legal, economic and
social aspects of study subjects. Study participants had no additional benefits, however
study findings had potential benefits to science and society including; the potential to
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estimate the prevalence of vitamin D deficiency in children with diabetes or obesity and
an attempt to relate the level of vitamin D to dyslipidemia in this population.

K.

Permission to Access Data
Permission was sought from the Institutional Review Board (IRB) of the Baystate

Medical Center, to share the de-identified data with study personnel at the University of
Massachusetts, Amherst.
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CHAPTER V

RESULTS

From the original study population of 743 participants, a total of 503 (67.7%)
were excluded and 240 (32.3%) included in the final study sample (Table 2). The
majority (n = 492, 66.2%) of the exclusions were due to a lack of vitamin D draw during
the study time period (Table 2). The majority of the participants (n = 175, 72.9%) were
vitamin D deficient with vitamin D levels ranging from 4.0 to 69.3 ng/ml, with a mean of
24.65 (standard deviation (SD) 10.33) (Table 3).
The majority of participants (60.8%) had normal total cholesterol (TC) measures
(mean TC; 167 mg/dL (34.68 SD)) (Table 4). Overall, across all age groups (2 to 21
years), half of the study sample (50%), had normal TG levels and 47 (19.6%) had high
TG levels. Half of the participants had sufficient HDL levels (49.6%) and (21.3%) had
low levels. Only 16 (6.7%) of had high LDL with the majority (62.1%) having normal
levels (Table 4).
The vitamin D deficient participants were more likely to be obese (42.2% body
mass index (BMI) ≥ 29.0) and (BMIZ score > 1.5) as compared to the patients with
normal vitamin D levels (26.2% obese) although this was not statistically significant
(p=0.121). Compared to patients with normal vitamin D levels mean weight, categorical
BMIZ, mean serum calcium (Ca), mean parathyroid hormone (PTH) levels and ethnicity
were significantly higher among vitamin D deficient patients (Table 5). On the contrary
age, sex (gender), height, body mass index (BMI), mean BMI Z-score (BMIZ), vitamin D
supplementation, glycated hemoglobin (HbA1C) and season did not differ significantly
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between patients with normal vitamin D levels and those with vitamin D deficiency
(Table 5).
We then evaluated whether covariates differed according to category of vitamin D
deficiency (Table 6). Our observations were similar to those previously described with
dichotomized vitamin D levels (Table 5), however, contrary to our prior observation age,
BMI, and height, differed significantly among patients according to categories of vitamin
D (Table 6). Specifically, severely vitamin D deficient participants were the oldest, tallest
and had the highest PTH levels (Table 6).
We then evaluated the distribution of covariates according to continuous vitamin
D levels; mean vitamin D levels differed significantly across categories of BMI, BMIZ,
season and ethnicity (Table 7). The lowest mean vitamin D level occurred in winter,
whiles the highest occurred in the summer season. Mean vitamin D levels were highest
and almost equivalent amongst Caucasian and Asian patients, as compared to African
Americans / Blacks (Table 7).
We then evaluated Pearson’s and Spearman’s correlation between continuous
covariates and vitamin D levels. Weight, body mass index Z-score (BMIZ) and
parathyroid hormone (PTH) were negatively and significantly correlated with vitamin D,
while age, height, serum calcium (Ca) and glycated hemoglobin (HbA1C), were not
significantly correlated (Table 8).
We then evaluated the distribution of covariates, according to normal vs.
abnormal blood lipid levels (Table 9). Patients with high mean glycated hemoglobin
(HbA1C) (poor control) were significantly more likely to have high TC as compared to
those with low HbA1C (P = 0.004) (Table 9). Patients who were younger and heavier
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were more likely to have high TG. Children who were Caucasian or Hispanic were more
likely to have high TG as compared to children who were African American/Black.
Patients who were heavier and those with acceptable glycated hemoglobin (HbA1C)
levels were more likely to have low HDL.
We then evaluated the correlation between vitamin D and covariates with blood
lipid levels (Table 10). Both vitamin D level and HbA1C were positively and
significantly correlated with total cholesterol (TC); (r = 0.18, P = 0.0084) and (r = 0.21, P
= 0.0049) respectively. Each unit increase in vitamin D level (vdl), resulted in a 21%
decrease in TG; (r = -0.21, P = 0.006), on the contrary a one kilogram increase in weight
and a unit increase in BMIZ lead to a corresponding increase in TG; (r = 0.22, P =
0.0038) and (r = 0.32, P =<0.0001) respectively (Table 10). Each unit increase in vitamin
D level (vdl), age or HbA1C, corresponded to an increase in HDL (Table 10). The
relationship between both weight and BMIZ with HDL were reversed and in both cases
the observed inverse correlation was statistically significant; (r= -0.35, P = <0.0001) and;
(r= -0.21, P =0.0074) respectively (Table 10). Additionally each unit increase in vitamin
D level (vdl), or height corresponded to a weak reverse effect on LDL levels; (r= -0.17, P
= 0.0265) and (r= -0.16, P = 0.0424) respectively (Table 10).
In a bivariate analyses we assessed the crude relationship between our exposure
variable (vitamin D dichotomized, categorized and continuous) and dichotomized levels
of each of the four outcome variables (blood lipids) (Table 11). Participants with
deficient levels of vitamin D were significantly more likely to have high TG, and low
HDL but less likely to have high TC and high LDL compared to those with normal
vitamin D levels (Table 11). Compared to patients with normal vitamin D levels, patients
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with either vitamin D insufficiency, moderate or severe vitamin D deficiency were more
likely to have low HDL, but less likely to have high TC, high TG and high LDL (Table
11). Mean vitamin D levels were more likely to lower among patients with high TG and
low HDL but similar among patients with high TC and high LDL in comparison to
vitamin D levels among patients with normal blood lipids (Table 11).
We then evaluated the association between vitamin D levels and the risk of
dyslipidemia (Table 12). In an unadjusted logistic regression model, moderately deficient
vitamin D patients had 1.68 times the odds of high total cholesterol compared to patients
with normal vitamin D levels (95% Confidence Interval (95% CI; 0.72 to 3.94). After
adjusting for age, BMIZ and HbA1C, findings were strengthened (OR = 2.9, 95% CI;
0.95 to 8.82) (Table 12). In an unadjusted logistic regression model, severely vitamin D
deficient patients had 3.5 times the odds of high triglycerides, compared to patients with
normal vitamin D levels (OR 3.50, 95CI% 1.25 to 9.79) (Table 12). A P- value for trend;
0.012 indicated a significant association between decreasing levels of vitamin D and the
odds of high triglycerides. Adjustment for PTH, BMIZ and ethnicity strengthened the
association, but confidence intervals were wide (OR 11.65, 95CI% 1.93 to 70.27) (Table
12). An overall trend of a positive association between decreased levels of vitamin D in
relation to the risk of high triglyceride was observed (P- value for trend = 0.006) (Table
12).
In an unadjusted logistic regression model, a protective effect of high triglyceride
was observed amongst patients with vitamin D levels above the mean value; irrespective
of adjustments for potential confounding; unadjusted OR; 0.95 (95% CI: 0.91 to 0.98)
and multivariable OR (0.91) adjusting for PTH, BMIZ and ethnicity 95% CI: 0.86 to 0.97
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(Table 12). In an unadjusted logistic analysis vitamin D deficient patients had 3.06 times
the odds of low high density lipoprotein as compared to patients with normal vitamin D
levels. This observed risk was attenuated after adjusting for BMIZ and ethnicity (OR =
2.51, 95% CI: 0.94 to 6.69) (Table 12). In an adjusted logistic regression analysis
moderately and severely vitamin D deficient patients had 4.02 and 5.24 times the odds of
low high density lipoprotein respectively, as compared to patients with normal vitamin D
levels (Table 12). After adjusting for confounding by BMIZ and ethnicity the risk
amongst moderately vitamin D deficient patients was elevated whiles an attenuated risk
was observed amongst severely vitamin D deficient patients (Table 12).
Finally, we evaluated the association between vitamin D levels and risk of
dylipidemia in a linear regression analysis (Table 13). After adjusting for potential
confounding by gender, HbA1C, ethnicity and season, a one ng/mL change in vitamin D
deficiency, vitamin D insufficiency, moderate or severe vitamin deficiency was
associated with a mean increase of 14.82 mg/dL, 11.8 mg/dL, 21.75 mg/dL and 17.68
mg/dL in total cholesterol levels respectively (Table 13). On the contrary a one unit
(ng/mL) change in continuous vitamin D levels was associated with a mean decrease of
0.58 mg/dL, in total cholesterol levels (Table 13). After adjusting for BMIZ, ethnicity
and parathyroid hormone (PTH), in comparison to patients with normal vitamin D,
deficiency in patients was positively associated with the risk of high triglycerides (TG)
(Table 13). A positive and significant association was observed between categorical
vitamin D levels and the risk of high TG, although the trend was not uniform across
strata; P value for trend = 0.002 (Table 13). Each one unit (ng/mL) reduction in vitamin
D levels was associated with a 2.14 mg/dL increase in high TG levels, P - value for trend
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= <0.001) (Table 13). Across strata of categorical vitamin D levels the magnitude of
association between vitamin D levels and the risk of low HDL, increased with decreasing
levels of vitamin D deficiency (Table 13). Similarly each one ng/mL increase in vitamin
D levels was associated with a 0.37 increase in the risk of low HDL, P - value for trend
(0.004) (Table 13). Lastly, each one ng/mL decrease in vitamin D levels was associated
with a mean increase of 0.51 mg/dL in the risk of high LDL, P - value for trend (0.019),
although there was no consistent association across increasing category of vitamin D
deficiency.
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CHAPTER VI

DISCUSSION

In this cross-sectional analysis of the relationship between vitamin D levels and
dyslipidemia, we observed that children and adolescents with moderate vitamin D
deficiency had an almost 3-fold increased risk of high TC compared to children with
normal vitamin D levels. Severe vitamin D deficiency was associated with a strong and
significant increased risk of low HDL as well as high TG as compared to children with
normal vitamin D levels; with a significant dose-response relationship. We did not
observe a statistically significant relationship between vitamin D deficiency and neither
high TC nor high LDL, however there was the suggestion of an increased risk. The lack
of association with high LDL could possibly be due to the small number of cases of high
LDL and therefore limited power. In addition, in linear regression analyses, we did find
that an increase in vitamin D deficiency was associated with a significant mean increase
in all four measures of dyslipidemia.

A.

Study Limitations

1.

Nondifferential Misclassification of Exposure
Although our measures of 25-hydroxy vitamin D levels (exposure) came from

validated standardized laboratory tests done at the Baystate Health Center’s laboratory,
the exposure assessment was via laboratory assays, for which there could have been a
slight chance of random measurement inaccuracies occurring as a result of human factors
such as analysis setup and interpretation and recording of results, which could have led to
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slight variations or inaccuracies in our 25-hydroxy vitamin D measures. These random
errors however should not have differed amongst our blood lipid levels in a systematic
way, hence it is unlikely that some non-differential misclassification of exposure could
have occurred via this avenue, which would have potentially led to an underestimation of
our effects estimates and biased our results towards the null value, by equally distorting
the true vitamin D levels amongst dylipidemia cases and non-cases. We categorized our
exposure (vitamin D levels), using widely used cutoff points to minimize the impact of
non-differential misclassification of exposure on our effect estimates. Hence within these
categories each participant’s, exposure level was accurately represented and a
comparison between these categories could then help minimize possible misclassification
between vitamin D categories in relation to dyslipidemia status. Additionally this error
was minimized by using trained laboratory personnel in obtaining our laboratory
measures on exposure.
Secondly, due to the observational measure of our study we used single
measurements of serum 25-hydroxy vitamin D as a proxy for the vitamin D status of our
study participants, although this is thought to be the best measure of vitamin D status and
hence is widely used. This measure however may not reflect long term vitamin D status,
because serum 25(OH) D, which indicates vitamin D made cutaneously as well as that
derived from diet and supplements has a half – life of 15 days (23). Hence, although we
collected data on vitamin D supplementation, our reliance on serum 25-hydroxy vitamin
D may have introduced some nondifferential misclassification in our evaluation of
vitamin D status. The occurrence of this nondifferential misclassification could have
potentially biased our results towards the null and thereby resulted in a reduction of the
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effect estimates for our relationship between 25-hydroxy vitamin D levels (25(OH) D)
and dyslipidemia in these children. The effect of this misclassification would have been
minimal, because proxy measures such as those we used are considered the best measure
of vitamin D status and is widely used and accepted in analysis.

2.

Nondifferential Misclassification of Outcome
Blood lipid levels were abstracted from laboratory results documented in medical

records for patients with a diagnosis of obesity and or type 1 and 2 diabetes mellitus
using specific International Classification of Disease version 9 (ICD 9) codes for these
two disease conditions. Also all cases of blood lipid levels were confirmed by a trained
investigator through chart review. Two trained physicians checked and verified the
outcome measures in the database. If during the data abstraction process however, cases
of dyslipidemia were incorrectly entered into the database, this could have attenuated our
effect estimates and biased our results towards the null, but the occurrence of this is
highly unlikely, because of the data verification steps employed to ensure that the data
was accurately abstracted from the medical charts and entered correctly into our database.
If some study participants did not fast 12 hours prior to their laboratory testing as
was required, their measurements of the abnormal blood lipid may have been artificially
elevated and not reflective of their true values and as such could have led to an
underestimation of the effect estimates and biased our results towards the null value. The
occurrence of this situation was highly unlikely because participants were advised to fast
before the laboratory testing and their fasting status was verbally ascertained prior to
testing via self report. Studies show that TG in particular is elevated postprandial
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although the physiological mechanism is poorly understood (24, 25). In contrast, in
comparison to fasting lipid profiles of the general population, Langsted et al. (2008)
observed negligible decreases in levels of TC, HDL and LDL measured postprandial
(25).
We relied on a single measurement of blood lipids, but both analytical
inaccuracies and imprecision resulting from laboratory methods of blood lipid assessment
as well as biologic or physiologic variation can influence blood lipid levels (26-28). In
terms of inaccuracy resulting from laboratory methods, previous repeatability (within-run
precision) and intermediate precision (total precision / between run precision / between
day precision) validation analyses done at the Baystate laboratory have indicated
relatively small coefficients of variation.
In terms of inaccuracy resulting from use of a single blood lipid measure to
accurately represent an individual’s long term blood lipid profile, Kafonek et al. (1992),
evaluated the biological variability in TC, HDL, LDL and TG. The authors calculated
physiological coefficients of variations (CVp) to take into account the total physiological
and analytical variations per patient from triplicate samples, taken at baseline from each
patient prior to lipid control treatment. They observed the following median physiological
coefficients of variation: 5.0% for TC, 17.8% for TG, 7.1% for HDL and 7.8% for LDL
and concluded that when triplicate blood samples are obtained in sequence, a single
measure of blood lipids obtained from these analysis will be representative of an
individual’s blood lipid levels within these ranges of precision (± 1, ±4, ± 11 and ± 8
CV% for TC, TG, HDL and LDL respectively) (27). It has been reported that physiologic
variation could result in a 3%, or 5% or 10% change in serum TC levels (26). Shumak et
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al (1993) suggests that a non linear decline in the CVs is noted with multiple lipid
sampling per person; the authors observed CVs ranging between approximately 4% to
10% for TC, 7% to 14% for LDL, 6% to 13% for HDL and 19% to 51% for TG (26).
Additionally, for example, the CV in females change from 8.6% to 6.5% after duplicate
cholesterol sampling done individually, and a 50% reduction in the CV can be obtained
from calculations from five cholesterol measures. Based on these observations Shumak et
al (1993), concluded that although repeated lipid measures prior to lipid control therapy
decisions have been suggested, very little precision is achieved via repeated
measurements.
In an evaluation of the impact of physiologic and analytical variations on the use
of a single lipid measure, to accurately assign risk categories in 51 individuals from
triplicate lipid samples, Bookstein et al. (1990) observed 5% day-to-day variability in
TC, 20% in TG, 10% in HDL and 8% in calculated LDL respectively (28). However,
Bookstein et al. (1990) also observed that, reliable TC and LDL measures , based on the
NCEP guidelines may be obtained from a single lipid measurement, if measured TC
levels were < 185 mg/dL or ranged between 215 to 225 mg/dL or was >225 mg/dL,
likewise for LDL, reliable measures could be obtained for LDL levels < 116 mg/dL or >
174 mg/dL from single lipid measures (28). Thus misclassification due to variations in
lipid levels may be unavoidable in the context of single or duplicate lipid level sampling,
and particularly when lipid levels fall within 10% of the documented NCEP cutoff points
(28).
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In summary, our use of single measurements of lipid values, which are susceptive
to physiologic (natural) variations, may have led to misclassification of patients risk
categories (26).

3.

Selection Bias
Due to the uniform admission of participants into our study, using a uniformly

applied selection criteria as defined by the availability of data on the first measured value
of 25 (OH) D levels within the study period, selection bias was highly unlikely in our
study. Also knowledge of the dyslipidemia of study participants was masked or unknown
to the physicians and investigator in the selection of study participants into the study. For
example, selection bias could only have occurred, if study participants were selected into
the study based on their diagnosis of dyslipidemia, which in this case was not the
situation, or if patients with vitamin D deficiency and dyslipidemia were sicker than other
patients and as such were more motivated to follow through with the physician referral
and hence had a higher chance of being selected into our study compared to other
participants. Although this was not the case, if this had happened it would have led us, to
miss some participants who had normal vitamin D levels or normal blood lipid levels.
This then could have led to an overestimation of our effects estimates and our results
would have been biased away from the null value, this we believe was an unlikely
occurrence in our study.
Another avenue for selection bias to have occurred in our study was due to the
fact that 492 patients (66.2%), out of the total original study sample of 743 (100%)
patients, were excluded from our final study sample due to lack of vitamin D draw in the
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study period. Ideally we would have liked to conduct a sensitivity analysis comparing the
characteristics of the excluded patients to those included in the final study sample, to
assess the potential of selection bias in our study via patient inclusion or exclusion
criteria. However, we were unable to do this because our study database lacked data on
the excluded patients.

4.

Information Bias
The physicians were blinded to the vitamin D and dyslipidemia disease status of

our study participants thus reducing the possible occurrence of information bias, through
the data validation process. Surveillance bias was also very unlikely in our study design
since the data collected was from laboratory records. No information was gathered from
the participants hence there was no possibility of recall bias in the exposure data
collection from our study participants. Another possibility of information bias would
have been due to variations in the assessments of individual measures of 25(OH) D levels
and blood lipid levels due to variations in the time at which each participant had these
measure taken. The time varied within our study period, hence some patients may have
been visiting the diabetes management clinic and receiving some counseling and if they
were compliant to the recommendations for a healthy lifestyle and as such had changed
their diet and lifestyle prior to the assessment of 25(OH) D) and blood lipid levels, the
additional counseling could have led these patients to modify lifestyle and diet which
would have impacted the blood test results. If this had happened then these patients could
for example have taken unprescribed vitamin D supplements or multivitamins or
intentionally eaten foods known to be vitamin D rich as well as low fat foods as a way of
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managing their vitamin D deficiency and dyslipidemia status which they had become
aware off after consulting with a physician. This could then have led to an
underestimation of their true effects estimates within our study period and biased our
results towards the null value, because they would have already started managing their
vitamin D levels and dyslipidemia status before data assessment was done for our study.

5.

Temporal Bias
One major limitation of our cross-sectional study design, due to its observational

nature was our lack of temporality between vitamin D levels and the risk of dyslipidemia
(temporal relationship between exposure and the occurrence of the disease). Hence
causality could not be established due to the difficulty in demonstrating if the vitamin D
deficiency preceded the dyslipidemia. Despite this inability to establish a cause-andeffect relationship the study granted us a hypothesis generating ability. In addition the
extreme obesity of the study participants may have masked the relevant associations
between vitamin D deficiency and dyslipidemia. This could have happened because
vitamin D is a fat soluble vitamin, hence when in excess it is stored in body fat, therefore
for individuals who were obese and had excess fat stores, the bulk of their vitamin D may
have been be trapped and stored in the excess fat hence, increasing their risk of vitamin D
deficiency (7). As such, the observed significant increase in odds of high TC, low HDL
as well as high TG amongst children and adolescents with below optimal vitamin D
levels compared to children with normal vitamin D levels, could possibly be due to the
fact that some of their serum vitamin D was being trapped within the elevated serum
blood lipid levels, implying a possible reverse causality. A randomized clinical trial
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would be needed to assess this possible reverse causality and thus ascertain the
relationship between vitamin D and dyslipidemia in these children and adolescents.

6.

Confounding
Within our multivariable linear and logistic regression model, we controlled for

and evaluated many known risk factors for dyslipidemia and other cardiovascular disease
risk factors recognized in literature as potential confounders of our vitamin D and lipid
levels association, using a Directed Acyclic Graph (DAG).
Adequate sunlight exposure and normal vitamin D levels are highly positively
correlated. Both vitamin D deficiency (exposure) and dyslipidemia (high TC, high TG,
high LDL and low HDL - disease) are independently and negatively associated with
adequate sunlight exposure. Yamazaki et al. (1998), observed significant increases (10.0
+ 6.7 to 38.9 + 38.0 pmol/cm2) in the levels of cholesterol hydro peroxides (Ch 7-OOHs)
in human skins after three hours of 10 – 40mJ/cm2/min of sunlight exposure (29). Hence
if adequate sunlight exposure was not accurately controlled for, it could have acted as a
confounder and would have led to an overestimation of our crude estimates (results) in
relation to the null value. We minimized this concern by evaluating data on seasons of
vitamin D level measurements within our models, this we did by collecting data on
exposure and outcome for participants within a two year period that encompassed
duplicates of the four seasons of the Northeastern US. Thereby reducing concerns
regarding for variations in vitamin D draws due to change in sunlight exposure as a result
of seasonal variations. Hence we believe that the occurrence of confounding due to
inadequate sunlight exposure evaluation in our study was highly unlikely.
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Our dataset did not include information on the physical activity of participants,
which is negatively and independently associated with both vitamin D deficiency and
dyslipidemia (high TC, high TG, high LDL and low HDL disease). Therefore not
controlling for it in our multivariable analysis could have led to an overestimation of the
association between vitamin D deficiency and dyslipidemia. We believe the effect of not
controlling for physical activity as a variable was minimized because we included BMI
and BMI Z-scores in our analysis and BMI is highly correlated with physical activity.
However, there is still likely residual confounding due to physical activity which we were
unable to adjust for because our dataset had no information on directly measured physical
activity of our patients.

7.

Generalizability
Our results may not be generalizable to the general population of children and

adolescents, but may only be generalized to children and adolescents aged 2 to 21 years,
with a diagnosis of type 1 and type 2 diabetes mellitus and / or obesity (BMI >95th
percentile), living in geographical regions or temperate countries with seasonal variations
similar to the Northeast US, with no gastrointestinal malabsorptive disorder (i.e. celiac
disease, cystic fibrosis) and no known parathyroid disease.
It has been established that vitamin D levels are lower in darker pigmented people
than light skinned people (7, 30). Hence, differences in skin pigmentation may cause
biological differences to exist in how vitamin D deficiency influences dyslipidemia and
thus possibly limit the generalizability of our findings to children and adolescents with
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skin pigmentations similar to that of our study population (mainly light skinned
participants).

B.

Consistency with Prior Literature
Despite immense recent interest in vitamin D deficiency and dyslipidemia in

children and adolescents, only three out of the eleven epidemiologic studies investigated
this association in children and adolescents ≤ 20 years old; Kumar et al (2009), Reis et al
(2009) and Ashraf et al (2009). Our findings were inconsistent with that of Kumar et al
(2009), who in their cross-sectional study design, observed amongst vitamin D
insufficient participants in comparison to vitamin D sufficient participants, a significant
difference in the decline in high density lipoprotein (HDL) (difference: -2.29 mg/dL;
95% CI -3.57 to -1.01, p = 0.001) and total cholesterol levels, (difference: -3.66 mg/dL;
95% CI -7.09 to -0.23, p = 0.04) respectively, additionally vitamin D deficiency was
observed to be associated with low levels of HDL cholesterol (difference: -3.03 mg/dL,
95% CI -5.02 to -1.04, p = 0.004) irrespective of adiposity or obesity. In contrast, we
found statistically nonsignificant odds ratios (OR) of 1.52 (95% CI 0.50 to 4.56) and OR
of 2.51 (95% CI 0.94 to 6.69) amongst vitamin D insufficient and deficient participants
respectively, in comparison to vitamin D sufficient participants in relation to the risk of
low HDL. We also observed no significant associations between vitamin D deficiency
amongst patients in comparison to normal vitamin D levels and the risk of high TC (OR
= 1.95; 95% CI: 0.85 to 4.46) .
Both Reis et al. and Ashraf et al. observed null findings in their cross-sectional
design studies. Despite their relatively large study sample, Reis et al. did not observe
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significant associations between levels (lowest quartiles compared to highest) of vitamin
D with either low high density lipoprotein (adjusted OR: 1.54, 95% CI: 0.99 to 2.39) or
high triglycerides levels (adjusted OR: 1.00, 95% CI: 0.49 to 2.04). Similarly, Ashraf et
al (2009), found no significant association between serum 25 (OH) vitamin D and either;
total cholesterol (r = -0.011, p = 0.94), triglycerides (r = 0.067, p = 0.64), HDL (r =
0.012, p = 0.94), or low density lipoprotein (r = 0.037, p = 0.80). In contrast we observed:
(r = 0.18, p = 0.0084), (r = -0.21, p = 0.006), (r = 0.22, p = 0.0039) and (r = 0.17, p =
0.0265) for the same comparisons. Differences in findings between our study and that of
these 3 prior studies among youth may be due to lack of consistency in the categorization
of both exposure and outcome, variations in covariate assessments such as inadequate
adjustment of confounding leading to the possibility of residual confounding, or
unevaluated effect modification and differences in study population characteristics and
distribution.
Although the biological mechanism linking vitamin deficiency to the risk of
dyslipidemia is still poorly understood, there are three proposed possible indirect
mechanisms. The first mechanism involves the activation of the vitamin D receptor; the
second mechanism is a possible consequence of the effect of statin drug therapy on the
disruption of the mevalonate pathway (HMG-CoA reductase pathway); and the third
mechanism is as a result of the elevation of peripheral insulin resistance in the body.

C.

Significance
Our findings relate vitamin D deficiency to dyslipidemia in children with diabetes

and obesity and add to the sparse body of literature in this area. We found that children
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and adolescents with varying levels of vitamin D deficiency had significantly increased
risk of high TC, low HDL, and high TG. Findings can inform more aggressive lifestyle
and dietary interventions with vitamin D supplementation to reduce the risk of
dyslipidemia in high risk children. Findings also shed light on the prevalence of vitamin
D deficiency in this unique population of children and adolescents.
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Table 1. Classification of study variables: Baystate Medical Children’s Hospital vitamin
D deficiency and dyslipidemia study, 2008 to 2010, (n=240).
Name
Description
Outcome variables

Type

TCcat

Total Cholesterol
≥ 180 mg/dL (high)
< 180 mg/dL (normal)

Dichotomous

TC

continuous TC

continuous

TGcatlo

Triglycerides (cut points for 2 to <10 years )
≥ 110mg/dL (high)
< 110mg/dL (normal)

Dichotomous

TGcathi

Triglycerides (cut points for 10 to 21 years )
≥ 130mg/dL (high)
< 130mg/dL (normal)

Dichotomous

Tgcatagett

Triglycerides: binary classification for all ages (2 to 21 years)
High
Normal

Dichotomous

TG

continuous TG

continuous

HDLcat

High density lipoprotein cholesterol
< 40mg/dL (low)
≥ 40mg/dL (sufficient)

Dichotomous

HDL

continuous HDL

continuous

LDLcat

Low density lipoprotein – cholesterol
≥ 130mg/dL (high)
< 130mg/dL (normal)

Dichotomous

LDL

continuous LDL

continuous

Exposure variable
VDLcat4

25-OH vitamin D levels
< 15.00 ng/ml
15.00 – 19.99 ng/ml
20.00 – 29.99 ng/ml
≥30.00 ng/ml

Categorical
(severe deficiency)
(moderate deficiency)
(25(OH)D insufficiency)
(normal or optimal)

VDLcat2

25-OH vitamin D deficiency
<30.00 ng/ml
(Deficient)
≥30.00 ng/ml
(Normal)

Dichotomous

VDL

Continuous vitamin D levels

Continuous
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Table 1. contd.
Covariates
Agecat2

Age at study enrollment and assessment
1= 2 to <10 years
2 = 10 to 21 years

Categorical

Age continuous

Individual ages at study enrollment and assessment

continuous

Sex

Gender
1 = Male
2 = Female

Dichotomous

Ca

Serum Calcium

Continuous

Wgt

Weight in kg.

Continuous

Hgt

Height in cm

Continuous

BMIcat4

Body Mass Index

Categorical
2

1 = BMI < 19.8 kg/cm

(Underweight)
2

2 = BMI 19.8 - 26.0 kg/cm

(Normal)
2

3 = BMI > 26.0 - 29.0 kg/cm (Overweight)
4 = BMI ≥ 29.0 kg/cm2

(Obese)

BMIZ

BMI Z score

Continuous

BMIZcat

BMI Z score categories
1 = BMIZ >1.5 (Overweight / Obese)
0 = BMIZ ≤1.5 (Normal)

Categorical

A1C

Glycated or glycosylated hemoglobin (HbA1C)

Continuous

A1Ccat

Glycated or glycosylated hemoglobin

Categorical

1 = HbA1C >8.0 (Bad HbA1C control)
0 = BMIZ ≤8.0 (Good HbA1C control)
PTH

Parathyroid Hormone

Continuous

VDS

Vitamin D supplementation
1= Yes
2= No

Categorical

SEASON

Seasons of the year in US
1= Winter
2= Spring
3= Summer
4= Fall

Categorical (Nominal)

ETH

Ethnicity
1 = Caucasian
2 = Asian
3 = African American / Black
4 = Hispanic / Latino
5 = Other

Categorical (Nominal)
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Table 2. Characteristics of Baystate vitamin D deficiency and dyslipidemia
2008- 2010 study population: inclusion and exclusion criteria (n=240)
N

%

743

100

492

66.2

Medical visits outside study dates

1

0.1

Medical based exclusion

7

0.9

Age exclusion (<2 age >21 years)

3

0.4

Multiple exclusion criteria

5

0.7

Total Excluded

503

67.7

Final study sample

240

32.3

Original study sample
Exclusion criteria
No vitamin D draw in study date range

By diagnostic group
Type I Diabetes

128

53.3

Type II Diabetes

13

5.4

Obesity

99

41.3
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Table 3. Distribution of 25-OH vitamin D measures and levels among Baystate
vitamin D, 2008- 2010 study population (n=240).
N

%

25-OH Vitamin D levels
<30.00 ng/ml

(Deficient)

175

72.9

≥30.00 ng/ml

(Normal)

65

27.1

N

%

25-OH Vitamin D levels
< 15.00 ng/ml

(Severe deficiency )

42

17.5

15.00 – 19.99 ng/ml

(Moderate deficiency)

46

19.2

20.00 – 29.99 ng/ml

(Insufficiency)

87

36.3

≥30.00 ng/ml

(Normal or Optimal)

65

27.1
Median

Mean (SD)

(Range)

24.65
25-OH Vitamin D measures (ng/ml)

(10.33)

50

23.2 (4 - 69.3)

Table 4. Distribution of blood lipid levels among Baystate vitamin D, 2008- 2010 study
population.
N

%

≥ 180 mg/dL (high)

69

28.8

< 180 mg/dL (normal)

146

60.8

Total

215

89.6

Mean (SD)

Median (Range)

167.0 (34.68 )

166 (77 -336)

≥ 110mg/dL (high)

10

29.4

< 110mg/dL (normal)

10

29.4

Total

20

58.8

≥ 130mg/dL (high)

37

18

< 130mg/dL (normal)

110

53.4

Total

147

71.4

High

47

19.6

Normal

120

50

Total

167

69.6

Mean (SD)

Median (Range)

109.0 (60.85)

91 (20 - 518)

< 40mg/dL (low)

51

21.3

≥ 40mg/dL (sufficient)

119

49.6

Total

170

70.8

Mean (SD)

Median (Range)

48.5 (13.46)

46 (20 - 88)

≥ 130mg/dL (high)

16

6.7

< 130mg/dL (normal)

149

62.1

Total

165

68.8

Mean (SD)
95.9 (29.93)

Median (Range)
94 (30 - 251)

Total Cholesterol (TC)

TC - continuous
Triglyceride (TG 2 to <10 years)

Triglyceride (TG 10 to 21 years)

Triglyceride (TG 2 to 21 years)

TG - continuous
High density Lipoprotein cholesterol (HDL-C)

HDL - continuous
Low density Lipoprotein cholesterol (LDL-C)

LDL - continuous

51

Table 5. Distribution of covariates according to dichotomous 25-OH vitamin D levels:
Baystate vitamin D 2008- 2010 study population (n = 240).
25-OH Vitamin D levels
Deficient
Normal
n
Age, categorized (Agecat2)
2 to <10 years
10 to 21 years
Age
Sex
Male
Female
Weight
Height
BMI
BMI < 19.8 (Underweight)
BMI 19.8 - 26.0 (Normal)
BMI > 26.0 - 29.0 (Overweight)
BMI ≥ 29.0 (Obese)
BMI Z-score (BMIZ)
BMIZ categorical
BMIZ > 1.5 (Obese)
BMIZ ≤ 1.5 (Normal)
Vitamin D supplementation
Yes
No
Serum Calcium (Ca)
Glycated hemoglobin (HbA1C)
HbA1C ≤ 8 (Acceptable)
HbA1C > 8 (Bad control)
Glycated hemoglobin (HbA1C)
Parathyroid Hormone (PTH)
Seasons of the year in US
Winter
Spring
Summer
Fall
Ethnicity
Caucasian
Asian
African American / Black
Hispanic / Latino
Other

p value*

175 (72.9%)

65(27.1%)

23(13.1%)
152 (86.9%)

11(16.9%)
54 (83.1%)

0.455

13.92 (3.55 SD)

14.76 (3.66 SD)

0.1055
0.985

81 (46.3%)

30 (46.2%)

94 (53.7%)
76.35 (32.71SD)
158.10 (16.14SD)

35(53.9%)
68.01 (22.29SD)
159.94 (13.07SD)

28 (16.2%)
52 (30.1%)
20 (11.6%)
73(42.2%)

11 (16.9%)
28 (43.1%)
9 (13.9%)
17(26.2%)

2.25(7.54SD)

1.31 (0.90SD)

104(60.5%)
68(39.5%)

28(43.1%)
37(56.9%)

0.0589
0.4121
0.121

0.3195
0.016

0.341
4 (2.3%)

3 (4.6%)

171 (97.7%)
9.83 (0.37SD)

62 (95.4%)
9.70 (0.48 SD)

85 (60.7%)
55 (39.3%)

30 (57.7%)
22 (42.3%)

7.80 (2.11 SD)

7.84 (1.47 SD)

0.9023

36.81 (14.99SD)

31.95 (8.70SD)

0.022

34 (19.4%)
33 (18.9%)

5 (7.7%)
10 (15.4%)

59 (33.7%)
49 (28.0%)

29 (44.6%)
21 (32.3%)

117 (77.0%)
6 (4.0%)
23 (15.0%)
3 (2.0%)
3 (2.0%)

56 (93.3%)
3 (5.0%)
1 (1.7%)
0 (0.0%)
0 (0.0%)

0.0479
0.704

0.103

0.029

* P value derived from two sample t test for continuous variables and from chi - square test for dichotomous or categorical variables.
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Table 6. Distribution of covariates according to categorical 25-OH Vitamin D levels: Baystate vitamin D, 2008-2010 study (n =
240).
25-OH Vitamin D levels
Moderate deficiency
Insufficiency
Normal
p value*
Severe deficiency
N(%)
N(%)
N(%)
N(%)
n
42 (17.5%)
46 (19.2%)
87 (36.3%)
65 (27.1%)
Age
0.025
2 to <10 years
1 (2.4%)
4 (8.7%)
18 (20.7%)
11 (16.9%)
10 to 21 years
41 (97.6%)
42 (91.3%)
69 (79.3%)
54 (83.1%)
Sex
0.985
Male
20 (47.6%)
22 (47.8%)
39 (44.8%)
30 (46.2%)
Female
22 (52.4%)
24 (52.2%)
48 (55.2%)
35 (53.9%)
BMI
<0.001
BMI < 19.8 (Underweight)
4 (9.5%)
5 (11.1%)
19 (22.1%)
11 (16.9%)
BMI 19.8 - 26.0 (Normal)
6 (14.3%)
11 (24.4%)
35 (40.7%)
28 (43.1%)
BMI > 26.0 - 29.0 (Overweight)
4 (9.5%)
6 (13.3%)
10 (11.6%)
9 (13.9%)
BMI ≥ 29.0 (Obese)
28 (66.7%)
23 (51.1%)
22 (25.6%)
17 (26.2%)
BMIZ categorical
<0.001
BMIZ > 1.5 (Obese)
34 (81.0%)
30 (68.2%)
40 (46.5%)
28 (43.1%)
8 (19.1%)
14 (31.8%)
46 (53.5%)
37 (56.9%)
BMIZ ≤ 1.5 (Normal)
Vitamin D supplementation
0.446
Yes
2 (4.7%)
0 (0.0%)
2 (2.3%)
3 (4.6%)
No
40 (95.2%)
46 (100.0%)
85 (97.7%)
62 (95.4%)
Table 6 continued on next page.
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Table 6 continued from previous page. Distribution of covariates according to categorical 25-OH Vitamin D levels: Baystate
vitamin D, 2008-2010 study (n = 240).
25-OH Vitamin D levels
Severe deficiency
Moderate deficiency
Insufficiency
Normal
p value*
N(%)
N(%)
N(%)
N(%)
Glycated hemoglobin (HbA1C)
0.209
HbA1C ≤ 8 (Acceptable)
22 (68.8%)
15 (45.5%)
48 (64.0%)
30 (57.7%)
HbA1C > 8 (Bad control)
10 (31.3%)
18 (54.6%)
27 (36.0%)
22 (42.3%)
Seasons of the year in US
0.343
Winter
8 (19.1%)
12 (26.1%)
14 (16.1%)
5 (7.7%)
Spring
10 (23.8%)
8 (17.4%)
15 (17.2%)
10 (15.4%)
Summer
12 (28.6%)
16 (34.8%)
31 (35.6%)
29 (44.6%)
Fall
12 (28.6%)
10 (21.7%)
27 (31.0%)
21 (32.3%)
Ethnicity
0.013
Caucasian
23 (62.2%)
25 (71.3%)
69 (86.3 %)
56 (93.3%)
Asian
2 (5.4 %)
1 (2.9%)
3 (3.8%)
3 (5.0%)
African American / Black
9 (24.3%)
7 (20.0%)
7 (8.8%)
1 (1.7%)
Hispanic / Latino
2 (5.4%)
1 (2.9%)
0 (0.0%)
0 (0.0%)
Other
1 (2.7%)
1 (2.9%)
1 (1.3%)
0 (0.0%)
Mean (SD)
Mean (SD)
Mean (SD)
Mean (SD)
Age
15.26 (±2.87)
13.89 (±2.87)
13.29 (±4.00)
14.76 (±3.66)
0.01
Weight
95.32 (±36.07)
80.51 (±30.78)
65.01 (±27.10)
68.01 (±22.29) <0.0001
Height
163.20 (±12.46)
159.32 (±14.01)
154.99 (±18.09) 159.94 (±13.07) 0.0264
BMIZ
4.42 (±15.06)
1.74 (±1.02)
1.45 (±1.09)
1.31 (±0.90)
0.0608
Serum Calcium (Ca)
9.85 (±0.32)
9.90 (±0.39)
9.79 (±0.38)
9.70 (±0.48)
0.1268
Glycated hemoglobin (HbA1C)
7.43 (±2.03)
8.51 (±2.69)
7.64 (±1.80)
7.84 (±1.47)
0.1137
Parathyroid Hormone (PTH)
46.63 (±18.89)
37.91 (±12.60)
31.78 (±11.59) 31.95 (±8.70)
<0.0001
* P- value derived from ANOVA for continuous variables and from chi square test for dichotomous or categorical variables

Table 7. Distribution of covariates according to continuous 25-OH Vitamin D
measures: Baystate vitamin D, 2008- 2010 study population (n=240).
25-OH Vitamin D continuous
Mean
SE
p value*
Age
2 to <10 years

0.2131
26.70

1.18

10 to 21 years
Sex
Male

24.32

0.75

24.44

0.96

Female
BMI
BMI < 19.8 (Underweight)

24.84

0.92

27.23

1.81

BMI 19.8 - 26.0 (Normal)

27.53

1.05

BMI > 26.0 - 29.0 (Overweight)

25.72

2.02

BMI ≥ 29.0 (Obese)

20.77

0.99

0.766

0.0001

BMIZ categorical

<0.0001

BMIZ > 1.5 (Obese)

22.22

0.83

BMIZ ≤ 1.5 (Normal)

27.90

1.03

Vitamin D supplementation

0.6113

Yes
No
Glycated hemoglobin (HbA1C)
HbA1C ≤ 8 (Acceptable)
HbA1C > 8 (Bad control)
Seasons of the year in US
Winter

26.61

4.29

24.60

0.68
0.8744

25.20
24.95

1.05
1.07

20.58

1.33

Spring

22.88

1.30

Summer

27.02

1.28

Fall

25.03

1.11

26.12
26.23
17.14

0.75
3.76
1.49

13.13
17.93

3.23
3.38

0.0066

Ethnicity
Caucasian
Asian
African American / Black

0.0001

Hispanic / Latino
Other

* P value derived from ANOVA for continuous variables and from chi square test for dichotomous or
categorical variables.
* a P value testing for statistical significance in trends.
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Table 8. Distribution of continuous covariates according to continuous 25-OH Vitamin D measures: Baystate vitamin D 20082010 study (n = 240).
25-OH Vitamin D continuous

56

Pearson correlation (r)

p value*

Spearman correlation (r)

p value*

Age

0.03

0.6025a

-0.01

0.9154

Weight

-0.27

<0.0001a

-0.28

<0.0001

Height

-0.03

0.6542a

-0.05

0.4734

BMIZ

-0.11

0.0917a

-0.32

<0.0001

Serum Calcium (Ca)

-0.1

0.152a

-0.1

0.1493

Glycated hemoglobin (HbA1C)

-0.03

0.7305a

0.04

0.5415

Parathyroid Hormone (PTH)

-0.31

<0.0001a

-0.29

<0.0001

a

* P value testing for statistical significance in trends (Pearson's)
* P value testing for statistical significance in trends (Spearman's)

Table 9 for TC and TG. Distribution of covariates according to dichotomous blood lipid levels: Baystate vitamin D 2008- 2010
study population (n = 240).
Total Cholesterol (TC mg/dL)
High
Normal
p value*
N
Age

69 (28.8%)

146 (60.8%)

High

Triglyceride (TG mg/dL)
Normal

47 (19.6%)

120 (50.0%)

0.896

0.021

2 to <10 years

9 (13.0%)

20 (13.7%)

10 (21.3%)

10 (8.3%)

10 to 21 years

60 (87.0%)

126 (86.3%)

37 (78.7%)

110 (91.7%)

14.83 (3.60SD)

13.92 (3.51 SD)

13.61 (3.84 SD)

14.52 (3.25 SD)

26 (37.7%)
43 (62.3%)

69(47.3%)
77 (52.7%)

22 (46.8%)
25 (53.2%)

49 (40.8%)
71 (59.2%)

75.48 (32.57 SD)
158.78 (13.98 SD)

72.70 (27.46 SD)
158.76 (15.40 SD)

84.99 (33.70 SD)
157.67 (14.68 SD)

76.12 (27.82SD)
160.24 (13.67 SD)

Age
Sex
Male
Female
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Weight
Height

0.0789
0.187

BMI

0.5149
0.996

0.0835
0.2865
0.024

BMI < 19.8 (Underweight)

10 (14.7%)

22 (15.1%)

2 (4.4%)

13 (10.8%)

BMI 19.8 - 26.0 (Normal)

24 (35.3%)

51 (34.9%)

8 (17.4%)

43 (35.8%)

BMI > 26.0 - 29.0 (Overweight)

7 (10.3%)

21 (14.4%)

7 (15.2%)

17 (14.2%)

BMI ≥ 29.0 (Obese)

27 (39.7%)

52 (35.6%)

29 (63.0%)

47 (39.2%)

BMIZ
BMIZ categorical
BMIZ > 1.5 (Obese)
BMIZ ≤ 1.5 (Normal)

2.99 (11.93 SD)

1.59 (1.01 SD)

4.31 (14.38 SD)

1.60 (1.00 SD)

35 (51.5%)
33 (48.5%

83 (57.2%)
62 (42.8%)

38 (82.6%)
8 (17.4%)

68 (57.1%)
51 (42.9%)

Table 9. Continued on next page:

0.1218
0.482

0.847

0.1599
0.43

p value*

0.0418
0.002

Table 9 for TC and TG. Continued from previous page: Distribution of covariates according to dichotomous blood lipid
levels: Baystate vitamin D 2008- 2010 study population (n = 240).
Total Cholesterol (TC mg/dL)
High

Normal

Vitamin D supplementation
Yes
No
Serum Calcium (Ca)
Glycated hemoglobin (HbA1C)

1 (1.5%)
68 (98.6%)
9.84 (0.39 SD)

5 (3.4%)
141 (96.6%)
9.77 (0.42 SD)

HbA1C ≤ 8 (Acceptable)

32 (55.2%)

HbA1C > 8 (Bad control)
Glycated hemoglobin (HbA1C)
Parathyroid Hormone (PTH)
Seasons of the year in US
Winter

Triglyceride (TG mg/dL)
p
value*
0.412

High

Normal

2 (4.3%)
45 (95.7%)
9.84 (0.43 SD)

4 (3.3%)
116 (96.7%)
9.77 (0.44 SD)

75 (65.8%)

23 (76.7%)

64 (68.1%)

26 (44.8%)

39 (34.2%)

7 (23.3%)

30 (31.9%)

8.35 (2.41 SD)

7.43 (1.68 SD)

0.004

6.81 (1.62 SD)

7.40 (1.82 SD)

0.1197

35.46 (12.51 SD)

35.71 (14.38 SD)

0.9065

35.12 (17.67 SD)

37.22 (12.79 SD)

0.4219

0.2644
0.175

0.151

0.393
0.371

0.484
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10 (14.5%)

27 (18.5%)

9 (19.2%)

18 (15.0%)

Spring
Summer
Fall
Ethnicity

9 (13.0%)
24 (34.8%)
26 (37.7%)

29 (19.9%)
56 (38.4%)
34 (23.3%)

6 (12.8%)
17 (36.2%)
15 (31.9%)

23 (19.2%)
51 (42.5%)
28 (23.3%)

Caucasian

50 (82.0%)

107 (83.0%)

38 (88.4%)

80 (76.9%)

Asian

4 (6.6%)

3 (2.3%)

1 (2.3%)

5 (4.8%)

African American / Black

7 (11.5%)

15 (11.6%)

2 (4.7%)

18 (17.3%)

Hispanic / Latino

0 (0.0%)

2 (1.6%)

2 (4.7%)

0 (0.0%)

0.418

0.044

Other
0(0.0%)
2 (1.6%)
0 (0.0%)
1 (1.0%)
* P value derived from two sample t test for continuous variables and from chi square test for dichotomous or categorical variables

Table 9. Continued on next page:

p
value*
0.773

Table 9 for HDL and LDL. Continued on next page: Distribution of covariates according to dichotomous blood lipid levels:
Baystate vitamin D 2008- 2010 study population (n = 240).
High Density Lipoprotein (HDL mg/dL)

n

Low

Sufficient

51 (21.3%)

119 (49.6%)

Age

p
value*

Low Density Lipoprotein (LDL mg/dL)
High

Normal

16 (6.7%)

149 (62.1%)

0.603

0.449

2 to <10 years

5 (9.8%)

15 (12.6%)

1 (6.3%)

19 (12.8%)

10 to 21 years

46 (90.2%)

104 (87.4%)

15 (93.8%)

130 (87.3%)

13.88 (3.29 SD)

14.47 (3.49 SD)

14.46 (3.60SD)

14.23 (3.45SD)

Age
Sex
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Male
Female
Weight
Height
BMI

0.3059
0.478

24 (47.1%)
27 (52.9%)
92.75 (35.21SD)
159.54 (14.59 SD)

49 (41.2%)
70 (58.8%)
71.89 (24.46SD)
159.69 (13.58 SD)

BMI < 19.8 (Underweight)

1 (2.0%)

BMI 19.8 - 26.0 (Normal)

63 (42.3%)
86 (57.7%)
77.62 (28.80SD)
159.53 (14.18SD)

16 (13.6%)

0 (0.0%)

15 (10.1%)

8 (15.7%)

45 (38.1%)

4 (25.0%)

46 (31.1%)

BMI > 26.0 - 29.0 (Overweight)

6 (11.8%)

17 (14.4%)

2 (12.5%)

22 (14.9%)

BMI ≥ 29.0 (Obese)

36 (70.6%)

40 (33.9%)

10 (62.5%)

65 (43.9%)

4.21 (13.79SD)

1.50 (1.01SD)

2.05 (0.83SD)

2.40 (8.13SD)

44 (88.0%)
6 (12.0%)

61 (51.7%)
57 (48.3%)

12 (75.0%)
4 (25.0%)

93 (63.3%)
54 (36.7%)

BMIZ
BMIZ categorical
BMIZ > 1.5 (Obese)
BMIZ ≤ 1.5 (Normal)

0.0346
<0.001

Table 9 for HDL and LDL continued on next page:

0.8026
0.553

8 (50.0%)
8 (50.0%)
87.31 (38.16SD)
159.34 (13.14SD)

<0.0001
0.9505
<0.001

p value*

0.2177
0.9576
0.401

0.8648
0.352

Table 9. Continued from previous page for HDL and LDL : Distribution of covariates according to dichotomous blood lipid levels:
Baystate vitamin D 2008- 2010 study population (n = 240).
High Density Lipoprotein (HDL mg/dL)
Low

Sufficient

Vitamin D supplementation

Low Density Lipoprotein (LDL mg/dL)

p
value*

High

Normal

0.856

0.557

Yes

2 (3.9%)

4 (3.4%)

1 (6.3%)

5 (3.4%)

No

49 (96.1%)

115 (96.6%)

15 (93.8%)

144 (96.6%)

9.81 (0.41SD)

9.79 (0.45SD)

9.94 (0.42SD)

9.79 (0.44SD)

Serum Calcium (Ca)
Glycated hemoglobin (HbA1C)

0.7235

p value*

0.005

0.2902
0.487
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HbA1C ≤ 8 (Acceptable)

29 (87.9%)

58 (61.7%)

6 (60.0%)

79 (70.5%)

HbA1C > 8 (Bad control)

4 (12.1%)

36 (38.3%)

4 (40.0%)

33 (29.5%)

6.26 (1.17SD)

7.65 (1.82SD)

0.0001

6.71 (1.52SD)

7.30 (1.82SD)

0.3242

35.90 (14.25SD)

36.27 (13.60SD)

0.8833

38.27 (6.47SD)

36.70 (14.79SD)

0.7283

Glycated hemoglobin (HbA1C)
Parathyroid Hormone (PTH)
Seasons of the year in US

0.187

0.214

Winter

12 (23.5%)

16 (13.5%)

1 (6.3%)

26 (17.5%)

Spring

8 (15.7%)

20 (16.8%)

1 (6.3%)

27 (18.1%)

Summer

22 (43.1%)

46 (38.7%)

7 (43.8%)

60 (40.3%)

Fall

9 (17.7%)

37 (31.1%)

7 (43.8%)

36 (24.5%)

Ethnicity
Caucasian
Asian
African American / Black

0.441
38 (86.4%)
0 (0.0%)
5 (11.4%)

83 (78.3%)
6 (5.7%)
15 (14.2%)

0.805
11 (78.6%)
0 (0.0%)
3 (21.4%)

105 (80.2%)
6 (4.6%)
17 (13.0%)

Hispanic / Latino
1 (2.3%)
1 (1.0%)
0 (0.0%)
2 (1.5%)
Other
0 (0.0%)
1 (1.0%)
0 (0.0%)
1 (0.8%)
* P value derived from two sample t test for continuous variables and from chi square test for dichotomous or categorical variables

Table 10. Pearson correlation of 25(OH)D and covariates with blood lipid levels: Baystate vitamin D, 2008- 2010 study
population (n = 240).
Total
Cholesterol
(TC mg/dL)

Triglyceride (TG
mg/dL)

High Density
Lipoprotein
(HDL mg/dL)

r
0.18

p value*

r

p value*

r

p value*

0.0084

-0.21

0.006

0.22

0.0039

0.1978

-0.05

0.5221

0.28

0.0002

0.8804

0.22

0.0038

-0.35

<0.0001

Height

0.09
0.01
0.05

0.4875

-0.07

0.3595

0.13

BMIZ

0.04

0.5921

0.32

<0.0001

Serum Calcium (Ca)

0.11

0.1315

0.05

Glycated hemoglobin (HbA1C)

0.21

0.0049

Parathyroid Hormone (PTH)
* P value testing for statistical significance in trends

0.01

0.9128

Vitamin D levels (vdl)
Age
Weight

Low Density
Lipoprotein
(LDL mg/dL)

61

r
0.17
0.02

p value*

0.8846

0.0805

0.01
0.16

-0.21

0.0074

0.02

0.8453

0.5464

-0.12

0.1512

0.15

0.0852

-0.13

0.1575

0.43

<0.0001

-0.1

0.2947

-0.1

0.2355

-0.01

0.9391

0.13

0.1278

0.0265
0.7605

0.0424

Table 11. Distribution of 25-OH Vitamin D levels among blood lipid levels: Baystate vitamin D 2008- 2010 study (n = 240).
TC

TG

High
N

Normal
%

N

High
%

pvalue

N

Normal
%

N

%

0.39

25-OH vitamin D - dichotomized

0.057

<30.00 ng/ml (Deficient)

53

76.8

104

71.2

39

83.0

82

68.3

≥30.00 ng/ml (Normal)

16

23.2

42

28.8

8

17.0

38

31.7

69

100.0

146

100.0

47

100.0

120

100.0

Total

0.402

25-OH vitamin D - categories
< 15.00 ng/ml

(Severe deficiency )

0.089

62

15

21.7

23

15.8

14

30

19

15.8

15.00 – 19.99 ng/ml (Moderate deficiency)

16

23.2

25

17.1

10

21.3

20

16.7

20.00 – 29.99 ng/ml (Insufficiency)

22

31.9

56

38.4

15

31.9

43

35.8

≥30.00 ng/ml

16

23.2

42

28.8

8

17

38

31.7

69

100.0

146

100.0

47

100.0

120

100.0

Mean

SE

Mean

SE

Mean

SE

Mean

SE

22.97

1.30

25.39

0.85

20.72

1.20

25.94

1.02

Median

Range

Median

Range

Median

Range

Median

Range

21

4.0 - 57.6

25

5.7 - 69.3

19.5

8.1 - 40.9

24.45

4.6 - 69.3

(Normal or Optimal)

Total

25-OH Vitamin D - continuous (ng/ml)

25-OH Vitamin D - continuous (ng/ml)

0.1139

* P - value derived from chi square test for dichotomous or categorical variables and from t test for continuous variables

Table 11. Continued on next page for HDL and LDL

pvalue

0.0041

Table 11 continued from previous page for HDL and LDL. Distribution of 25-OH Vitamin D levels among blood lipid
levels: Baystate vitamin D 2008- 2010 study (n = 240).
HDL-C

LDL-C

Low
N

Sufficient
%

N

%

High
pvalue

N

Normal
%

N

%

0.01

25-OH vitamin D - dichotomized

0.391

<30.00 ng/ml (Deficient)

44

86.3

80

67.2

13

81.3

106

71.1

≥30.00 ng/ml (Normal)

7

13.7

39

32.8

3

18.8

43

28.9

51

100.0

119

100.0

16

100.0

149

100.0

Total

0.005

25-OH vitamin D - categories
< 15.00 ng/ml

(Severe deficiency )

0.418

63

16

31.4

17

14.3

4

25.0

29

19.5

15.00 – 19.99 ng/ml (Moderate deficiency)

13

25.5

18

15.1

5

31.3

25

16.8

20.00 – 29.99 ng/ml (Insufficiency)

15

29.4

45

37.8

4

25.0

52

34.9

≥30.00 ng/ml

7

13.7

39

32.8

3

18.8

43

28.9

51

100.0

119

100.0

16

100.0

149

100.0

Mean

SE

Mean

SE

Mean

SE

Mean

SE

(Normal or Optimal)

Total

25-OH Vitamin D - continuous (ng/ml)

20.92

1.25

25.96

1.00

25-OH Vitamin D - continuous (ng/ml)

Median
18.7

Range
11.0 - 46.4

Median
25

Range
4.6 - 69.3

0.0042

* P value derived from chi square test for dichotomous or categorical variables and from t test for continuous variables

pvalue

21.46

2.67

24.8

0.88

Median
18.5

Range
6.7 - 45.9

Median
23.3

Range
4.6 - 69.3

0.237

Table 12. Odds Ratio of dyslipidemia by 25-OH Vitamin D levels: Bay State vitamin D
study, 2008 -2010 (n = 240).
Cases

Unadjusted

No.

%

OR

95% CI

16

23.2

1

Referent

P
trend

Multivariate
OR

P trend

95% CI

High Total Cholesterol (TC)
25-OH Vitamin D Normal
25-OH Vitamin D Deficient

53

76.8

1.34

0.69 - 2.60

25-OH Vitamin D Normal or Optimal

16

23.2

1

Referent

25-OH Vitamin D Insufficiency
25-OH Vitamin D Moderate deficiency
25-OH Vitamin D Severe deficiency
25-OH Vitamin D - continuous (Mean (SD))

22
16

31.9
23.2

1.03
1.68

0.39

1

Referent
a

0.12

0.48 - 2.20

1.95

0.85 - 4.46

1

Referent
a

0.62 - 3.83

a

0.95 - 8.82

a

2.41

0.78 - 7.44

1.53

0.72 - 3.94

2.90

0.114

0.062

15

21.7

1.71

0.72 - 4.08

22.97

10.84

0.98

0.95 - 1.01

0.115

0.97

0.93 - 1.01

0.094

8

17.0

1

Referent

0.061

1

Referent

0.231

High Triglyceride (TG)
25-OH Vitamin D Normal
25-OH Vitamin D Deficient

39

83.0

2.26

0.96 - 5.30

25-OH Vitamin D Normal or Optimal

8

17.0

1

Referent

1.91
0.012

b

1

0.66 - 5.47
Referent

b

0.006

25-OH Vitamin D Insufficiency

15

31.9

1.66

0.63 - 4.34

1.03

25-OH Vitamin D Moderate deficiency

10

21.3

2.38

0.81 - 6.96

3.30b

0.74 - 14.81

25-OH Vitamin D Severe deficiency

14

30.0

3.50

1.25 - 9.79

11.65b

1.93 - 70.27

20.72

8.20

0.95

0.91 - 0.98

0.005

0.91b

0.86 - 0.97

0.004

7

13.7

1

Referent

0.013

1

Referent

0.066

25-OH Vitamin D - continuous (Mean (SD))

0.31 - 3.45

Low High density Lipoprotein (HDL)
25-OH Vitamin D Normal
25-OH Vitamin D Deficient

44

86.3

3.06

1.27 - 7.42

25-OH Vitamin D Normal or Optimal

7

13.7

1

Referent

25-OH Vitamin D Insufficiency

15

29.4

1.86

2.51
0.001

0.69 - 5.02

c

1

0.94 - 6.69
Referent

1.52

c

0.50 - 4.56

c

1.43 - 17.88

0.013

25-OH Vitamin D Moderate deficiency

13

25.5

4.02

1.37 - 11.79

5.06

25-OH Vitamin D Severe deficiency

16

31.4

5.24

1.83 - 15.06

3.56c

1.03 - 12.33

20.92

8.92

0.95

0.91 - 0.98

0.005

0.96c

0.92 - 1.00

0.062

25-OH Vitamin D Normal

3

18.8

1

Referent

0.397

1

Referent

-

25-OH Vitamin D Deficient

13

81.3

1.76

0.48 - 6.48

-

-

25-OH Vitamin D Normal or Optimal

3

18.8

1

Referent

1

Referent

25-OH Vitamin D Insufficiency

4

25.0

1.10

0.23 - 5.20

-

-

25-OH Vitamin D Moderate deficiency

5

31.3

2.87

0.63 - 13.03

-

-

25-OH Vitamin D Severe deficiency

4

25.0

1.98

0.41 - 9.50

-

-

25-OH Vitamin D - continuous (Mean (SD))
High Low density Lipoprotein (LDL)

0.215

-

25-OH Vitamin D - continuous (Mean (SD))
21.46
10.67 0.97
0.92 - 1.02 0.236
b
c
adjusted for age, BMIZ and HbA1C
adjusted for PTH, BMIZ and ethnicity
adjusted for bmiz and ethnicity
P value testing for trends
* (-) due to lack of statistical power (small number of cases in each category), no covariates
were found to be confounding the observed relationship
a
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Table 13. Association between dyslipidemia by 25-OH Vitamin D levels: Baystate
vitamin D study, 2008 -2010 (n=240).
High Total Cholesterol (TC)
25-OH Vitamin D Normal
25-OH Vitamin D Deficient

Regression
coefficient

Standard error
(SE)

P trend

1

Referent

0.007

14.82

25-OH Vitamin D Normal or Optimal

a

1

25-OH Vitamin D Insufficiency

5.37
Referent

11.8

a

0.007

5.78

21.75

a

7.66

25-OH Vitamin D Severe deficiency

17.68

a

7.76

25-OH Vitamin D - continuous

-0.58a

0.25

0.022

1

Referent

0.013

25-OH Vitamin D Moderate deficiency

High Triglyceride (TG)
25-OH Vitamin D Normal
25-OH Vitamin D Deficient

30.91

25-OH Vitamin D Normal or Optimal

b

1

12.22
Referent

0.002

22.44

b

13.06

41.07

b

17.63

25-OH Vitamin D Severe deficiency

56.30

b

19.22

25-OH Vitamin D - continuous

-2.14b

0.59

<0.001

Low High density Lipoprotein (HDL)
25-OH Vitamin D Normal

1

Referent

0.188

25-OH Vitamin D Deficient
25-OH Vitamin D Normal or Optimal
25-OH Vitamin D Insufficiency

-3.78c
1
-0.61c

2.85
Referent
2.99

0.005

25-OH Vitamin D Moderate deficiency

-7.99c

4.00

25-OH Vitamin D Severe deficiency

-9.67

c

3.91

25-OH Vitamin D - continuous

0.37c

0.13

0.004

1

Referent

0.197

25-OH Vitamin D Insufficiency
25-OH Vitamin D Moderate deficiency

High Low density Lipoprotein (LDL)
25-OH Vitamin D Normal
25-OH Vitamin D Deficient

6.57

25-OH Vitamin D Normal or Optimal

d

1

25-OH Vitamin D Insufficiency

2.18

25-OH Vitamin D Moderate deficiency

Referent
d

13.35

d

d

25-OH Vitamin D Severe deficiency
25-OH Vitamin D - continuous

8.11
-0.50d

a

5.08

5.83
6.88
6.59
0.21

Multivariate model includes: gender, glycated hemoglobin (HbA1C), ethnicity and season.
Multivariate model includes: bmiz, ethnicity and parathyroid hormone (PTH).
c
Multivariate model includes: age, gender, bmiz, glycated hemoglobin (HbA1C), ethnicity and season.
d
Multivariate model includes: age, height and season. * P - value testing for statistical significance in trend
b
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0.093

0.019
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